Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324388 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of LY2189265 on Two Blood Pressure Drugs
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01324388 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 51 participants.
The verdict
NCT01324388, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2. To evaluate the effect of LY2189265 on heart rate and blood pressure in healthy volunteers when taken with a Beta-blocker drug (metoprolol). In Part 1, participants will receive four weekly injections of LY2189265 with continued use of normal lisinopril therapy. Part 2 is a cross-over study design. Participants will receive a single injection of LY2189265 in one period, and seven daily doses of metoprolol and a single injection of LY2189265 in another period.
Interventions
- DRUG Placebo
- DRUG Metoprolol
- DRUG Lisinopril
- BIOLOGICAL LY2189265
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324388
The ClinicalTrials.gov registry entry for NCT01324388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01324388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324388 about?
NCT01324388 is a clinical study titled "A Study of the Effect of LY2189265 on Two Blood Pressure Drugs". The purpose of this study is twofold: 1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril. 2. To evaluate the effect of LY2189265 on heart rate and blood pressure in h...
What is the current status of trial NCT01324388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2011-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01324388?
The interventions under investigation include: Placebo (DRUG), Metoprolol (DRUG), Lisinopril (DRUG), LY2189265 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01324388?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.